Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBio's heat shock protein progressing for arthritis

This article was originally published in Scrip

Executive Summary

CBio is around halfway to recruiting the 150 patients it needs for a new Phase IIa trial with a recombinant chaperonin 10 therapy for rheumatoid arthritis. The placebo-controlled study began in June at sites in Australia and New Zealand and is enrolling patients with active disease despite current therapy. The heat shock protein is thought to inhibit toll-like receptor signalling to prevent the over-expression of multiple pro-inflammatory cytokines, reducing immune cell activation and inflammation. The private Australian bioventure originally acquired rights from the University of Queensland and has also completed Phase IIa trials in psoriasis and multiple sclerosis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC031835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel